Find Out If You Have a Case

Attorney Matthew T. Marin

Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.

Super Lawyers® 2019–2022CALL 24/7(888) 348-2735

Dupixent Lawsuit — Free, Confidential Case Review

Dupixent lawsuit help for South Carolina patients

Marin & Murphy is licensed in South Carolina. Two confidential minutes tells you whether you have a case.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.

Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?

Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →

No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Attorney Matthew T. MarinOr talk to a person now: (888) 348-2735 — answered 24/7

Attorneys Stefanie A. Murphy and Matthew T. Marin of Marin & Murphy Law Firm

Stefanie A. Murphy & Matthew T. Marin

Partners

Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.

Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.

Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases from South Carolina residents. The core criterion is a diagnosis of cutaneous T-cell lymphoma (CTCL) or a qualifying T-cell lymphoma subtype made during or after Dupixent (dupilumab) use — there is no minimum length of use, and families may bring a claim through the estate of a loved one who has died. A South Carolina case becomes part of the federal consolidation in MDL 3180 in the District of New Jersey.

This page is about a lawsuit — it is not medical advice, and filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor.

Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.

Is Marin & Murphy Accepting Dupixent CTCL Cases From South Carolina?

Yes. Attorney Matthew T. Marin is admitted to practice in South Carolina. The Dupixent lawsuit is not a class action but a set of individual claims consolidated for pretrial proceedings as MDL 3180, and a South Carolina resident’s claim is evaluated on its own records: the pathology report establishing the diagnosis, the pharmacy and treatment history establishing Dupixent use, and the dates connecting the two. Whether a claim is accepted is determined after review, and no attorney-client relationship is created until a written engagement agreement is signed.

Who Qualifies From South Carolina?

The criteria are national, not state-specific — the full detail, including all fourteen qualifying T-cell lymphoma subtypes, is set out on the who qualifies page. In short:

Dupixent Lawsuit Qualification Checklist

  • You took Dupixent (dupilumab) — for any length of time; there is no minimum duration of use
  • You were diagnosed with cutaneous T-cell lymphoma (CTCL) or a qualifying T-cell lymphoma subtype during or after your Dupixent use
  • Claims may be brought for a family member who has died, through their estate
  • You are not currently represented by another attorney or law firm for this claim

Free Confidential Evaluation — No Fee Unless There Is a Recovery

Call (888) 348-2735 or use the confidential case review form on this page.

Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Who Is Included in the Filed Dupixent Cases? — South Carolina

Every Dupixent CTCL lawsuit filed in federal court now proceeds in one place, MDL 3180 in the District of New Jersey, regardless of where the plaintiff lives. Public docket indexes do not reliably show which member cases were brought by South Carolina residents: most complaints in the MDL are not available in the free public record, and the court a case was filed in says little about the plaintiff’s home state. Rather than guess, this page states what the record supports. The MDL 3180 tracker carries the current case count, how it is counted, and the latest docket activity; when a South Carolina resident’s complaint becomes publicly available, this section will describe it. Marin & Murphy Law Firm is licensed in South Carolina and reviews Dupixent CTCL claims from South Carolina residents directly; the criteria are described on do I qualify.

Where Would a South Carolina Dupixent Case Be Filed?

South Carolina has one federal district court: the United States District Court for the District of South Carolina. A Dupixent CTCL lawsuit filed there does not proceed alone: the Judicial Panel on Multidistrict Litigation has centralized these cases as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a South Carolina case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. Either route leads to the same consolidated proceeding, and your case remains an individual claim; an MDL is not a class action.

What Is the Filing Deadline for a South Carolina Dupixent Claim?

South Carolina’s general statute of limitations for personal-injury claims is three years under S.C. Code § 15-3-530(5). South Carolina applies a discovery rule: the period runs from the date the plaintiff knew or, by exercising reasonable diligence, should have known that she had a cause of action. None of that is a calculation to run on your own: accrual dates, the discovery doctrine, and the theory pleaded can each move the deadline, and reviewing those dates against your records is part of the free evaluation.

A wrongful-death claim carries its own three-year period that begins at death (S.C. Code § 15-3-530(6)).

How Common Is CTCL in South Carolina?

South Carolina is home to about 5.5 million people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 45 new CTCL diagnoses across South Carolina in a typical year. That rarity is exactly why a diagnosis deserves an individual look: statistics do not decide any single claim, and your medical records are what a review actually reads.

Free Confidential Evaluation — No Fee Unless There Is a Recovery

Call (888) 348-2735 or use the confidential case review form on this page.

Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Prefer to start online? The free case review takes about two minutes and asks only what the criteria turn on: your diagnosis, your Dupixent use, and their timing.

South Carolina Dupixent Lawsuit FAQs

Is Marin & Murphy accepting Dupixent CTCL cases from South Carolina?

Yes. Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases from South Carolina residents. The evaluation is free and confidential, and no attorney-client relationship is created until a written engagement agreement is signed.

Who qualifies to file from South Carolina?

The criteria are the same nationally: a diagnosis of cutaneous T-cell lymphoma or a qualifying T-cell lymphoma subtype during or after Dupixent use, with no minimum duration of use. Claims may also be brought through the estate of a family member who has died.

Where would a South Carolina Dupixent case actually be filed?

South Carolina’s federal court is the United States District Court for the District of South Carolina. Federal Dupixent CTCL cases are centralized in MDL 3180 in the District of New Jersey, so a South Carolina case is transferred there — or filed there directly where permitted — for coordinated pretrial proceedings, and it remains an individual claim throughout.

What is the deadline to file a South Carolina Dupixent claim?

Deadlines come from South Carolina statutes of limitation and related doctrine — the section above covers the framework. How it applies depends on the dates in your records, and reviewing them is part of the free evaluation.

What does it cost to bring a claim?

Representation is on a contingency basis: no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery; you are not responsible for them if there is no recovery, unless a court directs otherwise.

Has a court ruled that Dupixent causes CTCL? Is there a settlement?

No and no. Plaintiffs allege an association; published studies report a statistical association their authors note does not establish causation; the FDA is still evaluating a potential signal; and no settlement exists.

Do I have to stop taking Dupixent to file?

No. Filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor; this is a lawsuit question, not a medical one.

What is MDL 3180?

MDL 3180 is the federal multidistrict litigation consolidating Dupixent CTCL lawsuits for pretrial proceedings in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. Cases are coordinated for efficiency but remain individual claims — an MDL is not a class action.

South Carolina Dupixent Prescribing: The Publicly Reported Numbers

Dupixent (dupilumab) is widely prescribed in South Carolina, most often for atopic dermatitis and other inflammatory conditions. Federal drug-utilization data gives a state-level picture of how commonly the medication is used:

11,171Dupixent prescriptions reported by Medicaid in South Carolina in 2025
8,707Dupixent prescriptions reported by Medicaid in South Carolina in 2024
$45.2 millionMedicaid Dupixent reimbursement reported in South Carolina in 2025

Reported Medicaid prescriptions in South Carolina rose about 28% from 2024 to 2025. Because these figures capture only Medicaid outpatient utilization — not Medicare or private-insurance prescriptions — the full count of residents of South Carolina using Dupixent is higher. The totals also omit a small number of records suppressed for privacy.

Sources: Centers for Medicare & Medicaid Services, State Drug Utilization Data 2024 and 2025 (accessed August 21, 2026); In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, JPML Transfer Order, Schedule A (June 4, 2026). Utilization data reflects prescriptions reported by state Medicaid programs and is not evidence that any individual prescription caused injury.

Sources
  • U.S. Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by MDL Number (November 2, 2026) — jpml.uscourts.gov
  • MDL 3180 docket records — CourtListener dockets 72288297 (JPML) and 73443394 (D.N.J. 3:26-md-03180), reviewed September 15, 2026.
  • S.C. Code § 15-3-530(5) — South Carolina statute of limitations discussed above.
  • U.S. Census Bureau, Vintage 2024 Population Estimates (NST-EST2024), resident population as of July 1, 2024.
  • SEER program data: cutaneous T-cell lymphoma incidence ≈8.55 cases per million person-years.